PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2000 December; 1(4): 55–61.
Published online 2000 November 14. doi:  10.1208/pt010433
PMCID: PMC2750457

Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer

Abstract

DPC 963 is a non-nucleoside reverse transcriptase inhibitor with low aqueous solubility. The effect of DPC 963 drug substance particle size on the characteristics of granules manufactured by high-shear wet granulation was evaluated. The wet granulation process was used to manufacture a DPC 963 formulation with high drug loading. The formulation was manufactured using drug substance lots with different particle size distributions. Granulation particle size distribution, porosity, and compressibility were determined. A uniaxial compression test was also performed on moist compacts of the formulation prepared with different particle size distributions. Particle agglomeration behavior was affected by drug substance particle size. Granulation geometric mean diameter and fraction with particle size greater than 250 μm was inversely proportional to the drug substance particle size. Mercury intrusion porosimetry revealed higher pore volumes for the granules manufactured using the drug substance with the smaller particle size, suggesting lower tendency for granule densification than for that manufactured with the larger drug substance particle size. Granulation compressibility was also sensitive to changes in drug substance particle size. A decreased drug substance particle size led to increased granulation compressibility. Results from the uniaxial compression experiments suggested that the effect of particle size on granulation growth is the results of increased densification propensity, which in turn results from increased drug substance particle size.

KeyWords: Granulation, Porosity, Compressibility, Particle size

Full Text

The Full Text of this article is available as a PDF (254K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Corbett JW, Ko SS, Erikson-Viitanen S, et al. Discovery of HIV-1 non-nucleoside reverse transcriptase development candidates DMP 961 and DMP 963. AIDS. 1998;12(supp. 4):P21–P21.
2. Kristensen HG. Agglomeration of powders. Acta Pharm Suec. 1988;25:187–204.
3. Holm P, Schaefer T, Kristensen HG. Granulation in high-speed mixers. Part V. Power consumption and temperature changes during granulation. Powder Technol. 1985;43:213–223. doi: 10.1016/0032-5910(85)80002-4. [Cross Ref]
4. Kristensen HG, Holm P., Schaefer T. Mechanical properties of moist agglomerates in relation to granulation mechanism. Part I. Deformability of moist, desnsified agglomerates. Powder Technol. 1985;44:227–237. doi: 10.1016/0032-5910(85)85004-X. [Cross Ref]
5. Kristensen HG, Holm P, Schaefer T. Mechanical properties of moist agglomerates in relation to granulation mechanism. Part II. Effect of particle size distribution. Powder Technol. 1985;44:239–247. doi: 10.1016/0032-5910(85)85005-1. [Cross Ref]
6. Ouchiyama N, Tanaka T. The probability of coalescence in granulation kinetics. Ind. Engl. Chem. Process Des. Dev. 1975;14:286–289. doi: 10.1021/i260055a016. [Cross Ref]
7. Wikberg M, Alderborn G. Compression characteristics of granulated materials. VI. Pore size distributions, assessed by mercury penetration, of compacts of two lactose granulations with different fragmentations propensities. Pharm Res. 1992;84:191–195.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists